Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
Vanda Pharmaceuticals announced participation at the 2026 EADV Annual Meeting in Vienna with three poster presentations on imsidolimab. The posters cover neutrophil reduction and immunogenicity data in generalized pustular psoriasis (GPP), plus pustulation improvement results from the GEMINI-1 study.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.